Eli Lilly Inks $2.25B AI-Driven Enzyme Partnership with Profluent
On April 28, 2026, biotech startup Profluent and pharmaceutical giant Eli Lilly announced a multi‑program collaboration valued at up to $2.25 billion in upfront payments, milestones and royalties. The partnership focuses on AI‑designed enzymes for genetic medicines, including gene editors and delivery enzymes. The deal marks Lilly’s first large‑scale endorsement of treating biology as a generative compute problem.
AbbVie Secures Option to Acquire Kestrel Therapeutics for Up to $1.45B
AbbVie announced an exclusive right to acquire Kestrel Therapeutics, valued at up to $1.45 billion, contingent on Kestrel meeting development and regulatory milestones for its oral pan‑KRAS inhibitor KST‑6051. The agreement includes AbbVie funding the program and gives it the option...
PlaqueTec Raises $5M in Oversubscribed Financing Round
Cambridge‑based medtech company PlaqueTec raised $5M (£3.7M) in an oversubscribed financing round from its existing investors to develop its cardiovascular data lake, BioCarta. The funding will support building a proprietary data platform for precision medicine in atherosclerotic cardiovascular disease.
Fermeate Closes $2M Seed Round Led by Newfund Capital
California-based Fermeate, a startup using optogenetics to boost cell productivity in biomanufacturing, closed a $2 million seed round. The round was led by Newfund Capital and included investors SOSV, Ajinomoto Group Ventures, Ki Tua Fund, Heuristic Capital Partners, Momentum Capital,...
Avalyn Pharma Announces $182M IPO
Avalyn Pharma, a biotech developing inhaled versions of approved pulmonary fibrosis medicines, announced plans for an initial public offering targeting $182 million in proceeds. The IPO filing signals the company's move to public markets to fund its pipeline and expand...
Foamlab Raises $3.3M Growth Capital to Scale Bacterial Cellulose Foams
Foamlab, a Delft‑based startup developing bacterial cellulose foams as sustainable alternatives to fossil‑based plastics, announced a €3 million ($3.3 million) growth‑capital round. The round was led by ICOS Capital with participation from Value Factory Ventures, DOEN Ventures, Capricorn Industrial Biotech Fund and...
Ray Therapeutics Closes $125M Series B to Advance Vision‑Restoring Therapies
Berkeley‑based Ray Therapeutics, which develops optogenetic eye‑disorder therapies, closed a $125 million Series B round. The financing was led by Janus Henderson Investors with participation from Adage Capital Management, Franklin Templeton, Invus, Marshall Wace and the venture arms of MSD and Novo...
Kurma Partners Closes Biofund IV at $236M, Delivering Fresh Biotech Capital
Kurma Partners announced the final close of its Biofund IV at $236 million, below its $275 million target, creating a new source of capital for European biotech founders. The fund aims to back 16‑20 companies developing therapeutic solutions, building on Kurma’s hands‑on creation...
Amneal Pharmaceuticals to Acquire Kashiv BioSciences for Up to $1.1B
Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for up to $1.1 billion, comprising $375 million in cash, $375 million in equity and up to $350 million in contingent payments. The deal aims to create a fully integrated global biosimilars platform and...
Flagship Pioneering Funds New Biotech Serif Biomedicines with $50M
Flagship Pioneering launched Serif Biomedicines, a biotech startup focused on “modified DNA” medicines, providing the company with $50 million in funding. The capital will support preclinical development of its novel genetic medicine platform targeting rare diseases and immunology. Serif’s approach combines...
Eli Lilly Acquires Kelonia Therapeutics for $3.25B Upfront, up to $7B Total
Pharma giant Eli Lilly announced the acquisition of genetic‑medicine company Kelonia Therapeutics for an upfront payment of $3.25 billion, with potential milestone payments that could raise total consideration to $7 billion. Kelonia is developing an in‑vivo CAR‑T therapy for multiple myeloma. This...
Tortugas Neuroscience Raises $106M in Seed and Series A Round to Advance CNS Drug Pipeline
Tortugas Neuroscience announced a $106 million financing round spanning its seed and Series A rounds, led by Cure Ventures with co‑lead investors The Column Group and AN Venture Partners. The capital will fund development of four in‑licensed CNS drugs, including candidates from...
CEPI Grants $51M to Moderna for H5N1 Bird Flu Vaccine Trial
The Coalition for Epidemic Preparedness Innovations (CEPI) announced a £40 million (≈$51 million) grant to fund a Phase 1 trial of Moderna’s mRNA vaccine against the H5N1 bird‑flu strain. In return, Moderna pledged to supply the vaccine quickly and affordably to low‑ and...
UCB to Acquire Neurona Therapeutics for Up to $1.15B to Advance Cell Therapy for Epilepsy
Belgian biopharma UCB announced it will acquire clinical‑stage biotech Neurona Therapeutics for up to $1.15 billion. The deal gives UCB access to NRTX‑1001, a cell‑based therapy in Phase I/II trials for drug‑resistant mesial temporal lobe epilepsy. The transaction is expected to close...
Samsung Biologics Acquires GSK's Vaccine R&D Assets for $280M
South Korea’s Samsung Biologics agreed to purchase the vaccine R&D facility assets of UK‑based GSK in Maryland for $280 million, marking the biotech giant’s entry into the US market. The transaction was secured by Maryland state and county officials after GSK...
Roche Invests $20M in C4 Therapeutics to Advance DAC Cancer Therapy
Roche has committed $20 million to C4 Therapeutics to deepen a partnership focused on developing degrader‑antibody conjugates (DACs) for cancer treatment. The strategic investment, announced in mid‑April 2026, aims to accelerate early‑stage DAC research and could expand to a $1 billion collaboration.
Orthogon Therapeutics Secures $11M Follow‑On Funding
Orthogon Therapeutics announced the closing of a follow‑on financing round of $11 million, bringing its total capital raised to $36 million. The funds will support the continued development of its first‑in‑class drug targeting BK polyomavirus, a major cause of complications in transplant...
Trevi Therapeutics Raises $150M in Share Sale
Biotech company Trevi Therapeutics announced it has raised $150 million by selling shares in an underwritten offering. The capital will support the company's development pipeline and growth initiatives. The deal was announced on April 17, 2026.
Nula Therapeutics Secures $10M Series A From Apollo Health Ventures and $20M ARPA‑H Grant
New York‑based biotech startup Nula Therapeutics announced it has raised $10 million in a Series A round led by Apollo Health Ventures, alongside a $20 million grant from the U.S. Advanced Research Projects Agency for Health (ARPA‑H) to study aging. The funding will...
Beeline Medicines Raises $300M Series A Led by Bain Capital to Advance BMS‑licensed Immunology Pipeline
Beeline Medicines announced a $300 million Series A financing round, led by Bain Capital, to fund its immunology and inflammation drug pipeline licensed from Bristol Myers Squibb. The Stamford‑Boston startup will develop candidates such as afimetoran (BMS‑986256) for systemic lupus erythematosus and other...
MeiraGTx Reacquires Bota‑vec Gene Therapy Rights From Johnson & Johnson for $25M
MeiraGTx announced it is buying back the rights to its bota‑vec gene therapy for X‑linked retinitis pigmentosa from Johnson & Johnson, paying $25 million upfront with a future milestone and royalties. The deal follows a failed Phase 3 trial but MeiraGTx believes...
STORM Therapeutics Raises $56M Series C to Advance RNA-Modification Cancer Therapy
Cambridge-based biotech STORM Therapeutics announced a €47.5 million ($56 million) Series C round from existing investors including M Ventures, Pfizer Ventures, Taiho Ventures, IP Group, UTokyo Innovation Platform and Fast Track Initiative. The funding will support the Phase 2 trial...
Roche to Acquire SAGA Diagnostics for Up to $595M
Roche announced a definitive merger agreement to acquire SAGA Diagnostics, the developer of the Pathlight tumor‑informed MRD platform, for up to $595 million, including milestone payments. The acquisition will integrate SAGA’s platform into Foundation Medicine’s portfolio, expanding Roche’s cancer monitoring capabilities....
Uluu Secures $2.1M Australian Government Grant to Scale Seaweed‑based Plastic Alternative
Perth biotech startup Uluu has been awarded a $2.1 million grant from the Australian Government’s Industry Growth Program to accelerate commercial‑scale production of its seaweed‑based plastic alternatives. The funding will enable the company to increase output tenfold and support trials with...
Revolution Medicines Raises $2B in Concurrent Stock and Debt Offerings
Revolution Medicines announced a $2 billion financing, combining a stock offering and debt issuance, to fund its development of daraxonrasib for advanced pancreatic cancer. The raise exceeds the company's original target and supports further clinical progress.
StarLight Therapeutics Secures $2.0M Seed Funding
European venture studio AQYLA BioVentures launched its first programme, STARLIGHT Therapeutics, which secured €1.8 million (approx $2.0 million) in seed funding. The round supports the development of retinal disease therapies and was announced as part of AQYLA's new biotech venture studio model.
Terremoto Biosciences Raises $108M in Series C Financing Round
San Francisco‑area biotech Terremoto Biosciences announced a $108 million Series C financing round. New investors RA Capital Management, Deep Track Capital, Osage University Partners and BeOne Medicines joined existing backers OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant Asset Management. The capital...
Biogen to Acquire Apellis in $5.6B Buyout
Biogen announced a $5.6 billion acquisition of Apellis, expanding its portfolio beyond neurology. The deal was detailed in a recent filing, confirming the transaction is set to close. The acquisition positions Biogen in new therapeutic areas.
Harbinger Health Raises $100M to Advance Cancer Detection Technology
Harbinger Health, a startup developing cancer‑detection tests, announced a $100 million financing round to accelerate its technology. The funding will support further development and commercialization of its cancer‑detection platform. The round was announced on April 14, 2026.
Alamar Biosciences Files for up to $154M Nasdaq IPO
Alamar Biosciences, a California biotech developing a proteomics‑based biomarker platform, announced plans to sell 9.4 million shares at $15‑$17 each on Nasdaq under the ticker ALMR, targeting a raise of $133‑$154 million to fund commercial expansion and manufacturing capacity.
Eli Lilly to Acquire CrossBridge Bio for up to $300M
Eli Lilly announced on Tuesday it will acquire cancer‑focused antibody‑drug conjugate startup CrossBridge Bio for up to $300 million. The deal, involving biotech entrepreneur Michael Torres, aims to strengthen Lilly’s oncology pipeline. The acquisition was disclosed on 14 April 2026.
Clean Food Group Secures $6.5M Investment to Scale Yeast‑based Oils
Clean Food Group has raised £4.5 million ($5.6 million) in equity from Clean Growth Fund and New Agrarian, plus a £700,000 ($0.9 million) non‑dilutive grant from Innovate UK. The funding will accelerate the ramp‑up of its world‑largest yeast‑based oils and fats facility in Knowsley,...
Reme-D Secures $500,000 From Global Innovation Fund to Expand Molecular Diagnostics
Egyptian biotech startup Reme-D, which develops room‑temperature PCR testing kits, has raised $500,000 from the Global Innovation Fund. The funding will be used to scale manufacturing, expand into Nigeria and Libya, and advance R&D in genetic disease, oncology, and maternal...
NeoMorph Raises $100M for Molecular Glues
San Diego-based NeoMorph announced a $100 million funding round to advance its molecular glue drug discovery platform. The capital will support further development and clinical programs. The round was announced on April 13, 2026.
Oricell Therapeutics Raises $110M in Pre-IPO Financing
Oricell Therapeutics, a China-based developer of CAR‑T therapies for solid tumors, announced it has raised over $110 million in a pre‑IPO financing round. The capital will fund the advancement of its GPC3‑targeted autologous CAR‑T program and support the company's planned public...
BDC Capital Launches $110M Life Sciences Fund
Canada’s Business Development Bank of Canada (BDC) announced the launch of a new $150‑million CAD (≈$110 million USD) life sciences fund, managed by BDC Capital. The fund will target seed‑ and Series A‑stage biotech and medical‑technology companies, with initial investments of $1‑3 million...
Avalyn Pharma Files for IPO to Fund Pulmonary Fibrosis Treatments
Avalyn Pharma, a biotech developing inhaled formulations of approved pulmonary fibrosis drugs, announced it has filed for an initial public offering. The company aims to raise capital to fund its late-stage development work and bring its treatments to market.
DeepCyte Raises $1.5M Seed Round to Advance AI-Driven Single-Cell Toxicology
DeepCyte, a techbio startup, announced the close of a $1.5 million seed round to fund its AI-powered toxicology platform MetaCore and the DeeImmuno solution for drug development. The funding will support scaling the high-throughput single-cell metabolomics technology and further AI...
Basilea Pharmaceutica Secures $6M Non‑dilutive Grant From CARB‑X for Novel Antibiotic BAL2420
Swiss biotech Basilea Pharmaceutica announced it has received an additional US$6 million non‑dilutive grant from the non‑profit accelerator CARB‑X to fund the Phase I trial of its novel Gram‑negative antibiotic BAL2420. The funding follows six years of CARB‑X support and enables the...
Gilead to Acquire Tubulis for ~$5B
Gilead has entered into a definitive agreement to acquire Tubulis, an ADC research organization, for an upfront $3.15B plus up to $1.85B in contingent milestone payments, totaling roughly $5B. The acquisition will expand Gilead’s ADC capabilities and add next‑generation assets...
VION Biosciences Closes Acquisition of Cellular Technology Limited (CTL)
VION Biosciences announced the closing of its acquisition of Cellular Technology Limited (CTL), a provider of functional immune‑monitoring analyzers, software, consumables, and services. The deal expands VION’s capabilities in immune‑medicine, adding CTL’s ELISPOT and FluoroSpot platforms and recurring consumables, strengthening...
Life Biosciences Raises $80M to Fund Anti‑aging Gene Therapy Clinical Trial
Life Biosciences, a startup co‑founded by Harvard biologist David Sinclair, announced it has raised $80 million to support a clinical test of its anti‑aging gene therapy. The funding will be used to develop a one‑time treatment aimed at rewinding cellular aging,...
Jeito Capital Closes Record $1.2B Europe-Focused Biopharma Fund
France-based Jeito Capital has closed its second fund, raising €1 billion ($1.2 billion), the largest ever for an independent European biopharma fund. The Jeito II fund will back 15‑20 clinical‑stage biopharma companies across Europe, with investment caps up to €150 million per company.
Sidewinder Therapeutics Raises $137M in Series B Round
San Diego‑based ADC biotech Sidewinder Therapeutics announced it has closed a $137 million Series B financing to advance its bispecific antibody‑drug conjugate platform. The new capital will fund pipeline development and expand the company’s capabilities. The round was disclosed on April 8, 2026.
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, a Bay Area biotech known for its VYKAT XR therapy for Prader‑Willi syndrome. The deal gives Neurocrine its first metabolic‑disorder therapy and aims to accelerate its obesity drug pipeline. Soleno will...
Korsana Biosciences to List on NASDAQ via Reverse Merger with Cyclerion Therapeutics
Neuroscience firm Korsana Biosciences announced a reverse‑merger with NASDAQ‑listed Cyclerion Therapeutics, creating a combined company that will trade under the ticker KRSA. The all‑stock transaction gives Korsana shareholders about 98.5% of the equity, with Cyclerion shareholders retaining 1.5%, and includes...
Syneron Bio Closes $150M Series B Funding Round
Syneron Bio, a biotech firm developing AI-enabled macrocyclic peptide discovery, announced the close of a $150 million Series B round. The round was led by an undisclosed international life sciences fund with co-lead investors Decheng Capital and CDH VCG, and...
Beam Therapeutics Secures $500M Senior Secured Loan From Sixth Street
Beam Therapeutics announced a $500 million senior secured, long‑term non‑dilutive financing agreement with Sixth Street to support the potential commercial launch of its Risto‑Cel therapy. The deal provides a minimum $200 million drawdown and extends the company's runway through mid‑2029....
SV Health Investors Acquires EpiVax, Expanding Healthcare Portfolio
SV Health Investors, a private healthcare investment firm, announced the acquisition of EpiVax, a bioanalytical CRO specializing in immunogenicity risk assessment for pharma and biotech companies. The deal, announced on April 2, 2026, adds a new platform investment to SVHI’s...
Aspect Biosystems Secures $58M Canadian Government Funding for Diabetes Cell Therapy
Vancouver-based biotech startup Aspect Biosystems announced it has received $58 million in funding from the Government of Canada to advance its diabetes cell therapy platform. The grant aims to keep the breakthrough development in Canada and accelerate clinical progress, supporting...